MGTA surges on preliminary data from cell mobilization study
Magenta posts positive preliminary results from mid-stage multiple myeloma study
May 12, 2021 10:23 AM ETMagenta Therapeutics, Inc. (MGTA)By: Aakash Babu, SA News Editor
Magenta Therapeutics (MGTA +0.8%) announces positive preliminary results from its Phase 2 clinical trial of MGTA-145 plus plerixafor in patients with multiple myeloma.
The investigator-initiated, 25-patient Phase 2 open-label clinical trial is designed to evaluate the ability of the drug combination to mobilize and collect stem cells for autologous stem cell transplant in patients with multiple myeloma.
All patients (10/10) met the primary endpoint of mobilization and collection of 2 million CD34+ stem cells per kg in up to two days of same-day mobilization and apheresis.
All transplanted patients (6/6) successfully engrafted, with median recovery of neutrophils after 12 days and platelets after 17 days, which are within transplant expectations in multiple myeloma.
The trial continues to enroll patients and Magenta expects to report additional data at the EHA Congress, as well as at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in June.
Bladerunner
